← All stories
Markets
Arbutus plans $230 million share buyback via tender offer
2 outlets - including Investing and Financialpost - are covering this story. WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modif…
Covered by 2 outlets
All coverage · 2 articles
Investing.com UK
·2h ago
Arbutus plans $230 million share buyback via tender offer
Financial Post
·2h ago
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
WARMINSTER, Pa., Aug. 21, 2026 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modif…